InflaRx (IFRX) Stock Price, News & Analysis

Company Overview

InflaRx N.V. is a biotechnology company that develops therapies for inflammatory and autoimmune diseases. Its research focuses on the complement system, a part of the immune system that can contribute to inflammation and tissue damage.

The company’s lead antibody, vilobelimab, targets the complement protein C5a. In 2023, the U.S. Food and Drug Administration granted emergency use authorization for vilobelimab, marketed as Gohibic, for certain hospitalized adults with COVID-19. InflaRx is also investigating the drug in other inflammatory conditions.

Founded in 2007, InflaRx is headquartered in Jena, Germany, and has operations in the United States. Co-founder Niels C. K. Riedemann has served as the company’s chief executive officer.

Key Stats

• Today's Range: $1.17 to $1.30
• 50-Day Range: $1.18 to $2.29
• 52-Week Range: $0.80 to $2.95
• Volume: 577,453 shs
• Average Volume: 1.12 million shs
• Market Capitalization: $173.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.43
• Consensus Rating: Moderate Buy

InflaRx Stock Analysis - MarketRank™

InflaRx scored higher than 42% of companies evaluated by MarketBeat, and ranked 640th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

InflaRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 5 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

InflaRx has a consensus price target of $7.43, representing about 529.5% upside from its current price of $1.18.

Amount of Analyst Coverage

InflaRx has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for InflaRx are expected to decrease in the coming year, from ($0.22) to ($0.31) per share.

Price to Book Value per Share Ratio

InflaRx has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.41% of the float of InflaRx has been sold short.

Short Interest Ratio / Days to Cover

InflaRx has a short interest ratio ("days to cover") of 15.02, which indicates bearish sentiment.

Change versus previous month

Short interest in InflaRx has recently increased by 0.89%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InflaRx does not currently pay a dividend.

Dividend Growth

InflaRx does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.58

News Sentiment

InflaRx has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for InflaRx this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for IFRX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

1 people have added InflaRx to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InflaRx insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.39% of the stock of InflaRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/03/2026
• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IFRX
• CIK: 1708688
• Web: www.inflarx.de
• Phone: 493641508180
• Fax: 49-36-4150-8181
• Employees: 65
• Year Founded: 2006

Price Target and Rating

• Average Price Target for InflaRx: $7.43
• High Price Target: $14.00
• Low Price Target: $2.00
• Potential Upside/Downside: +529.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.63 million
• Net Margins: N/A
• Pretax Margin: -149,706.05%
• Return on Equity: -32.04%
• Return on Assets: -27.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.26
• Quick Ratio: 7.26

Sales & Book Value

• Annual Sales: $30 thousand
• Price / Sales: 5,796.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.13 per share
• Price / Book: 1.04

Miscellaneous

• Outstanding Shares: 147,370,000
• Free Float: 123,347,000
• Market Cap: $173.90 million
• Optionable: Optionable
• Beta: 2.38